NAV
₹350.6441
as of 13 Nov 2026
Expense Ratio
1.27%
Lumpsum returns (CAGR)
- 1Y
- +2.29%
- 3Y
- +11.82%
- 5Y
- +10.60%
- Since Inception
- +17.74%
SIP returns (XIRR)
- 1Y
- +8.01%
- 3Y
- +6.62%
- 5Y
- +11.60%
- Since Inception
- +14.39%
Performance Comparison
Sectoral allocation
as of 30 Sept 2026- Pharmaceuticals & Biotechnology9.60%
- Banks8.54%
- Industrial Products7.01%
- Retailing6.50%
- Finance6.21%
- Consumer Durables6.15%
- Electrical Equipment5.56%
- Auto Components5.50%
- IT - Software5.34%
- Capital Markets4.55%
- Realty3.08%
- Chemicals & Petrochemicals2.99%
Each sector links to the mutual funds most exposed to it.
Thinking about UTI Mid Cap Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Portfolio holdings
portfolio shared with UTI Mid Cap Fund-Growth Option
- 1Coforge Ltd3.01%
- 2Au Small Finance Bank Ltd2.75%
- 3Blue Star Limited2.55%
- 4Aurobindo Pharma Ltd.2.24%
- 5Ajanta Pharma Ltd.2.15%
- 6Apl Apollo Tubes Ltd2.11%
- 7Federal Bank Ltd.1.98%
- 8Phoenix Mills Ltd1.95%
- 9Info-Edge (India) Ltd.1.92%
- 10Shriram Finance Ltd1.92%
What this fund does
UTI Mid Cap Fund · Direct · Growth seeks to generate long-term capital appreciation by investing in mid-cap companies — ranked 101st to 250th by market capitalisation. These companies offer a balance of growth potential and relative stability, with wider price swings than large-caps.
About This Fund
UTI Mid Cap Fund · Direct · Growth is a Mid Cap mutual fund offered by UTI Mutual Fund. The fund has been operational for over 13 years. It benchmarks its performance against Nifty Midcap 150 TRI. The current expense ratio is 1.27%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations